AOD 9604 (5mg)

What is Dragon Pharma Peptide AOD 9604?
Dragon Pharma AOD 9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176–191. Unlike full-length growth hormone, AOD 9604 was developed to isolate and enhance the lipolytic (fat-reducing) properties of hGH without significantly stimulating insulin-like growth factor-1 (IGF-1) or promoting systemic growth effects. Supplied in a lyophilized peptide vial, it is intended for controlled research applications involving fat metabolism, obesity models, and metabolic regulation studies. Preclinical and early clinical investigations explored its ability to stimulate fat breakdown (lipolysis) and inhibit fat cell formation (lipogenesis). Because it does not significantly increase circulating growth hormone levels, AOD 9604 has been studied as a targeted metabolic peptide rather than a traditional anabolic or growth-promoting agent. It remains a research compound without approved therapeutic indications in many regions.

Mechanism of Action:
AOD 9604 mimics the fat-reducing segment of growth hormone, selectively activating pathways associated with lipolysis while minimizing interaction with IGF-1 signaling. It is believed to stimulate beta-3 adrenergic receptors in adipose tissue, promoting the breakdown of stored triglycerides into free fatty acids for energy utilization. At the same time, AOD 9604 may inhibit lipogenesis, reducing the formation of new fat cells. Unlike full-length growth hormone, it does not significantly affect blood glucose regulation or stimulate generalized tissue growth. Research suggests that AOD 9604 exerts its metabolic effects without strongly impacting the hypothalamic-pituitary axis, making it distinct from systemic GH therapies. However, as most data come from preclinical and limited human studies, comprehensive long-term safety and efficacy profiles are still under evaluation.

Benefits:

• Supports lipolysis and fat metabolism in research models
• May inhibit lipogenesis and adipocyte formation
• Does not significantly elevate IGF-1 levels
• Minimal impact on systemic growth hormone pathways

Research Applications:

• Investigation of obesity and metabolic disorder models
• Study of fat metabolism regulation mechanisms
• Research on selective growth hormone fragment activity
• Exploration of non-anabolic peptide-based fat loss strategies

Dosing Instructions:

• Dosing: Research protocols typically use 300–500 mcg per administration
• Daily Dose: Administered once or twice daily in research studies
• Route: Subcutaneous (SC) injection
• Duration: Commonly 4–12 weeks depending on study design
• Frequency: Daily or as specified per experimental protocol
• Recommended Cycles: Determined by research objectives, often 4–12 weeks
• PCT: Not applicable; follow lab-specific research guidelines

Stacking With Other Products:

• Often researched alongside CJC-1295 for metabolic studies
• May be combined with Ipamorelin in peptide research protocols
• Studied with GLP-1 receptor agonists in obesity-related models
• Avoid stacking with unregulated compounds outside controlled settings

Side Effects:

• Mild injection-site irritation
• Possible transient headaches
• Rare reports of nausea
• Limited long-term human safety data available

Contraindications:

• Pregnancy or breastfeeding
• Active malignancy
• Severe metabolic or endocrine disorders
• Hypersensitivity to peptide components

Conclusion
Dragon Pharma AOD 9604 represents a specialized growth hormone fragment peptide designed to target fat metabolism without exerting full systemic GH effects. By stimulating lipolysis and reducing lipogenesis, it has attracted interest in metabolic and obesity-related research. Unlike anabolic hormones, AOD 9604 does not significantly elevate IGF-1 or suppress endogenous testosterone, positioning it as a metabolically focused compound rather than a growth-promoting agent. While early studies demonstrated promising fat-reduction activity, long-term human data remain limited, and regulatory approval for therapeutic use is not established in many regions. As with all research peptides, strict adherence to sterile preparation, accurate dosing, and controlled protocols is essential for investigative applications.

References:

• Ng FM, et al. "AOD 9604 and Its Effects on Lipolysis and Fat Metabolism." Obesity Research.
• Heffernan MA, et al. "Growth Hormone Fragment 176-191 in Metabolic Regulation." Endocrinology Journal.
• World Anti-Doping Agency (WADA) Prohibited List – Growth Hormone Fragments.
• ClinicalTrials.gov – AOD 9604 in Obesity and Metabolic Research Studies.

AOD 9604 FAQ

✔️ What is AOD 9604?
AOD 9604 is a peptide fragment derived from human growth hormone (HGH), designed to support fat metabolism and weight management without the growth-promoting effects of full HGH.

✔️ How does AOD 9604 work?
It targets fat cells, encouraging lipolysis (fat breakdown) and reducing fat accumulation, making it popular for weight management and body composition improvement.

✔️ What are the main benefits of AOD 9604?
Users report enhanced fat metabolism, improved energy, and support for lean muscle maintenance, making it a preferred choice in fitness and wellness protocols.

✔️ How should AOD 9604 be stored?
Keep the vial refrigerated at 2–8°C, protect from light and moisture, and ensure the vial remains sealed to maintain potency and stability.

✔️ How is AOD 9604 administered?
It is typically reconstituted with bacteriostatic water and administered via subcutaneous injection, using sterile equipment and following safe handling procedures.

✔️ Are there any side effects?
When used correctly, AOD 9604 is generally well-tolerated. Some users may experience mild redness or irritation at the injection site, but systemic side effects are rare.

✔️ Can AOD 9604 be stacked with other peptides?
Yes, it is often used alongside other fat-burning or muscle-supporting peptides to enhance body composition goals, but always follow professional guidance.

✔️ Is AOD 9604 legal and safe?
It is legal in many regions as a research peptide, but regulations may vary. Always purchase from reputable sources like Dragon Pharma Peptides and consult a health professional before use.

Storage and Safety – Dragon Pharma AOD 9604

Maintaining proper storage and ensuring safety are crucial for preserving the potency, purity, and effectiveness of Dragon Pharma AOD 9604. Follow these guidelines for optimal results:

Storage Guidelines

• Keep the vial refrigerated at 2–8°C (36–46°F).
• Protect from direct sunlight, heat, and humidity.
• After reconstitution with sterile water, store the solution in the refrigerator and avoid freezing.
• Always keep vials sealed when not in use to maintain stability.

Handling Safety

• Use sterile gloves or clean hands to prevent contamination.
• Administer with disposable syringes for single-use only.
• Keep out of reach of children, pets, and unauthorized individuals.
• Follow recommended dosage guidelines and adhere to research or medical protocols.

Important Notes

• Improper storage or handling can reduce biological activity.
• Always ensure the peptide is used in a safe and controlled environment.
• Maintaining proper safety practices ensures the effectiveness and longevity of AOD 9604.